Compare ODTX & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ODTX | PGY |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | 503 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2025 | 2021 |
| Metric | ODTX | PGY |
|---|---|---|
| Price | $16.85 | $13.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $34.67 | $29.45 |
| AVG Volume (30 Days) | 291.0K | ★ 1.8M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 116.43 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $1,301,360,000.00 |
| Revenue This Year | N/A | $12.99 |
| Revenue Next Year | N/A | $16.38 |
| P/E Ratio | ★ N/A | $11.25 |
| Revenue Growth | N/A | ★ 26.07 |
| 52 Week Low | $15.10 | $10.40 |
| 52 Week High | $29.05 | $26.80 |
| Indicator | ODTX | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 27.93 |
| Support Level | $15.73 | $12.46 |
| Resistance Level | $19.60 | $16.42 |
| Average True Range (ATR) | 1.69 | 1.01 |
| MACD | -0.19 | -0.41 |
| Stochastic Oscillator | 6.10 | 1.67 |
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.